Key Dates

Related Announcements

• October 4, 2022 - NIDA REI: Reaching Equity at the Intersection of HIV and Substance Use: Novel Approaches to Address HIV Related Health Disparities in Underserved Racial and/or Ethnic Populations (R01 Clinical Trial Optional). See NOFO RFA-DA-23-061.
• October 4, 2022 - NIDA REI: Reaching Equity at the Intersection of HIV and Substance Use: Novel Approaches to Address HIV Related Health Disparities in Underserved Racial and/or Ethnic Populations (R34 Clinical Trial Optional). See NOFO RFA-DA-23-062.
• August 9, 2022 - NIDA REI: Addressing Racial Equity in Substance Use and Addiction Outcomes Through Community-Engaged Research (R01 Clinical Trial Optional). See NOFO RFA-DA-23-013.
• August 9, 2022 - NIDA REI: Racial Equity Visionary Award Program for Research on Substance Use and Racial Equity (DP1 Clinical Trial Optional). See NOFO RFA-DA-23-026.
• August 9, 2022 - NIDA REI: Research on Neurocognitive Mechanisms Underlying the Impact of Structural Racism on the Substance Use Trajectory (R61/R33 Clinical Trial Optional). See NOFO RFA-DA-23-028.
• August 9, 2022 - NIDA REI: Research at Minority Serving Institutions on Neurocognitive Mechanisms Underlying the Impact of Structural Racism on the Substance Use Trajectory (R61/R33 Clinical Trial Optional). See NOFO RFA-DA-23-029.
• August 9, 2022 - NIDA REI: Racial Equity Visionary Award Program for Research at Minority Serving Institutions on Substance Use and Racial Equity (DP1 Clinical Trial Optional). See NOFO RFA-DA-23-031.
• August 9, 2022 - NIDA REI: Addressing Racial Equity in Substance Use and Addiction Outcomes Through Community-Engaged Research at Minority Serving Institutions (R01 Clinical Trial Optional). See NOFO RFA-DA-23-032.

Issued by

National Institute on Drug Abuse (NIDA)

Purpose

The purpose of this Notice is to announce virtual “office hours” for potential applications who may apply for any of the NIDA Racial Equity Initiative funding opportunities on July 25, 2024 from 2:00-3:00pm ET.

The NIH is committed to supporting health equity research to 1) improve minority health and reduce health disparities in the United States and 2) remove the barriers to advancing health disparities research (for more information, see: NIH's statement on ending structural racism and the NIH/NIMHD Strategic Plan). In alignment with this NIH-wide effort, NIDA established the Racial Equity Initiative (REI), with goals that include promoting racial equity in NIDA’s research portfolio. Among the actions taken by NIDA, which were informed by internal and external meetings and listening sessions, the Institute has committed to a significant increase in funding for research to address disparities in outcomes related to drug use and HIV. The REI funding opportunity announcements seek to advance equity by supporting research and research training efforts that are consistent with NIDA’s mission and with best practices for conducting research with racial and ethnic minority populations.

The Notices of Funding Opportunity (NOFOs) included in the Office Hours are: 

Racial Equity Visionary Award Program (DP1)

• RFA-DA-23-026:NIDA REI: Racial Equity Visionary Award Program for Research on Substance Use and Racial Equity (DP1 Clinical Trial Optional)
• RFA-DA-23-031: NIDA REI: Racial Equity Visionary Award Program for Research at Minority Serving Institutions on Substance Use and Racial Equity (DP1 Clinical Trial Optional) 

Community Engaged Research Projects (R01)

• RFA-DA-23-013: NIDA REI: Addressing Racial Equity in Substance Use and Addiction Outcomes Through Community-Engaged Research (R01 Clinical Trial Optional)
• RFA-DA-23-032: NIDA REI: Addressing Racial Equity in Substance Use and Addiction Outcomes Through Community-Engaged Research at Minority Serving Institutions (R01 Clinical Trial Optional) 

Neurocognitive Mechanisms and Structural Racism (R61/R33)

• RFA-DA-23-028: NIDA REI: Research on Neurocognitive Mechanisms Underlying the Impact of Structural Racism on the Substance Use Trajectory (R61/R33 Clinical Trial Optional)
• RFA-DA-23-029: NIDA REI: Research at Minority Serving Institutions on Neurocognitive Mechanisms Underlying the Impact of Structural Racism on the Substance Use Trajectory (R61/R33 Clinical Trial Optional) 

HIV and Substance Use (R34 and R01)

• RFA-DA-23-061: NIDA REI: Reaching Equity at the Intersection of HIV and Substance Use: Novel Approaches to Address HIV Related Health Disparities in Underserved Racial/Ethnic Populations (R01 Clinical Trial Optional)
• RFA-DA-23-062: NIDA REI: Reaching Equity at the Intersection of HIV and Substance Use: Novel Approaches to Address HIV Related Health Disparities in Underserved Racial/Ethnic Populations (R34 Clinical Trial Optional)

Office Hours Information

July 25, 2024 from 2:00-3:00pm ET

Those interested in joining the office hours are strongly encouraged to review the recording of the pre-application technical assistance webinar that was held on September 26, 2022 and the Frequently Asked Questions webpage prior to the office hours. The office hours will be a time to ask questions to Program Officials about the NOFOs and application process. There will be a breakout room available for each of the NOFO pairs above and applicants may move between breakout rooms if they have questions about more than one NOFO.

The Office Hours will not be recorded. Applicants who cannot attend or have additional questions may contact NIDA staff outside the office hours. Please direct questions to the scientific contact for the NOFO in which you are interested.

Registration is required. Please register using this link: https://nih.zoomgov.com/meeting/register/vJItcu6grzwiEuwgBk9G6RUt5tBiXA838Wk

After registering, you will receive a confirmation email containing information about joining the meeting.

Inquiries

Please direct all inquiries to:

Alexa Romberg, Ph.D.
National Institute on Drug Abuse (NIDA)
Telephone: 301-435-0264
Email: alexa.romberg@nih.gov

Vani Pariyadath, Ph.D.
National Institute on Drug Abuse (NIDA)
Telephone: (301) 443-3209
Email: vani.pariyadath@nih.gov